In a previous study, CDA treatment to activate STING protected 50% of mice implanted with immunogenic B16 melanomas until experimental end points and surviving mice all acquired stable protective antitumor immunity.11 As CDA treatment was initiated when B16 tumors were relatively small (~100 mm3) in this prior study, we next tested if CDA treatment was more effective in mice with smaller LLC tumors. The gene discussed is CDA; the disease is melanoma.